The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19
Year: 2024
Type: article
Study design: Clinical Trial
Abstract: /kg of NK cells. All participants' clinical status and inflammation markers were monitored. No serious adverse events were reported after infusion. Exploratory outcomes included the donor chimerism, NK-cell immunophenotype evolution, and immune lymphocyte reconstitution. This study provides preliminary evidence supporting the idea that treatment of COVID-19 patients with moderate/severe symptoms using NK from COVID-19 convalescent donors is feasible and safe.
Source: iScience
Authors: Clara Hernández-Blanco, Karima Al-Akioui-Sanz, Lara Herrera, Cristina Aguirre-Portolés, Daniel Lozano-Ojalvo, Leticia Pérez-Rodriguez, Jordi Cano-Ochando, Pilar Guerra-García, Alejandro Martín-Quirós, José Luis Vicario, Silvia Santos, Miguel Ángel Pérez-Vaquero, Miguel Ángel Vesga, Alberto M. Borobia, Antonio J. Carcas, Antonio Balas, Miguel Ángel Moreno, Rebeca Pérez de Diego, Mercedes Gasior, Bernat Soria, Cristina Eguizabal, Antonio Pérez-Martínez
Institutions: Hospital Universitario La Paz, Hospital La Paz Institute for Health Research, Spanish National Cancer Research Centre, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Instituto de Salud Carlos III, Osakidetza, Instituto de Investigación en Ciencias de la Alimentación, Icahn School of Medicine at Mount Sinai, Comunidad de Madrid, Universidad Autónoma de Madrid, Universitat de Miguel Hernández d'Elx
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,150
Awards: G1175115578, G1338257350, G1341303, G1422035950, G1622782223, Nuevos tratamientos para inmunodeficiencias primarias con defectos en celulas NKs: desde la edición génica a la terapia celular, G1937947940, G2051642515, G210041235, G2262748287, Modelar in vitro Inmunodeficiencias Primarias con defectos en células NK, G2601397997, G2672435700, Terapia celular combinada para pacientes COVID-19 de alto riesgo de mortalidad (DECODE-19), G300979063, G3053252003, G34346518, G3480869486, G3627981058, G3681454997, G4042783231, G410571670, G425668148, G441457905, G451917667, G5080475149, G5195188938, G5522270315, G5539308778, CAR-NK ""off the shelf"": nuevas mejoras y perspectivas de inmunoterapia contra cánceres hematológicos en recaída o refractarios. Ensayo clínico fase I para evaluar la viabilidad y seguridad de la terapia CD19-CAR-NK alogénicas para pacientes con leucemia o, G5967599077, G6122222817, G6323293759, G7084143925, G7195972392, G7349005999, G7566811974, G792975244, G8223520544, G833184845, G8696694383, G929308097
OpenAlex ID: W4405844039